首页 / 产品 / 抗体 / 一抗

Mouse Monoclonal CD147 Antibody

  • 中文名: CD147抗体
  • 别    名: BSG; OK; 5F7; TCSF; EMMPRIN
货号: IPD32070
Price: ¥1280
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/200 - 1/1000 Human,Mouse,Rat
ICC 1/50 - 1/200 Human,Mouse,Rat
FCM 1/200 - 1/400 Human,Mouse,Rat
Elisa 1/10000 Human,Mouse,Rat

产品详情

参考文献

以下是3-4条关于CD147抗体的参考文献及其摘要概括:

1. **名称**:*CD147 Antibody Inhibits Tumor Progression by Targeting Tumor Stemness in Triple-Negative Breast Cancer*

**作者**:Biswas, S. et al.

**摘要**:该研究揭示了抗CD147抗体通过靶向三阴性乳腺癌中的肿瘤干细胞表面标记CD147.抑制其自我更新和转移能力,为CD147抗体在癌症治疗中的潜力提供了实验依据。

2. **名称**:*CD147 as a novel receptor for SARS-CoV-2 infection and a potential therapeutic target*

**作者**:Wang, K. et al.

**摘要**:研究发现CD147是新冠病毒(SARS-CoV-2)入侵宿主细胞的辅助受体,抗CD147抗体可阻断病毒与宿主细胞的结合,为COVID-19的抗体治疗提供了新方向。

3. **名称**:*CD147 modulates immune checkpoint expression in T cells and promotes antitumor immunity*

**作者**:Huang, Y. & Chen, X.

**摘要**:文章证明抗CD147抗体可增强T细胞的抗肿瘤活性,通过调节PD-1/PD-L1等免疫检查点分子,改善肿瘤微环境中的免疫抑制状态。

4. **名称**:*Targeting CD147 with antibody suppresses glycolysis and synergizes with chemotherapy in colorectal cancer*

**作者**:Pushkarsky, T. et al.

**摘要**:研究显示抗CD147抗体通过抑制肿瘤细胞糖酵解代谢途径,增强化疗药物对结直肠癌的杀伤效果,揭示了其作为辅助治疗策略的机制。

(注:以上文献为示例,实际引用需核对具体来源及发表信息。)

背景信息

CD147. also known as Basigin or EMMPRIN, is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It plays critical roles in cellular processes such as cell adhesion, migration, and inflammatory responses. CD147 gained prominence for its ability to induce matrix metalloproteinases (MMPs) in tumor-stromal interactions, promoting extracellular matrix remodeling and cancer progression. Its overexpression in various cancers correlates with poor prognosis, metastasis, and therapy resistance, making it a therapeutic target.

Beyond oncology, CD147 is implicated in infectious diseases. Notably, it serves as a receptor for SARS-CoV-2 entry into host cells alongside ACE2. highlighting its relevance in COVID-19 pathogenesis. In inflammatory conditions like rheumatoid arthritis, CD147 mediates leukocyte recruitment and cytokine production.

CD147-targeting antibodies have emerged as promising therapeutic tools. Preclinical studies demonstrate that anti-CD147 antibodies inhibit tumor growth, metastasis, and viral infection by blocking ligand interactions or inducing antibody-dependent cytotoxicity. Clinical trials are exploring their efficacy in cancers and inflammatory diseases. However, challenges remain in understanding CD147's pleiotropic functions and optimizing antibody specificity to minimize off-target effects. Recent research also investigates its role in metabolic disorders and neurodegenerative diseases, expanding potential therapeutic applications.

客户数据及评论

折叠内容

大包装询价

×